Advances in Microbiome-Based Therapies for Recurrent C difficile Infection

Experts provide an overview of the gut microbiome and its importance to nutrition and overall health.

Joseph Reilly, BS, PharmD, BCGP; Candace Cotto, RN; and Andrew Skinner, MD, review C. difficile infection (CDI), its risk factors, symptoms, and quality of life for the patient.

Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.

Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.

Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.

Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.

Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.

Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.